Nieves Martinez Lago: Omitting Bolus 5-FU in GI Cancer Chemotherapy – A Meta-Analysis
Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared on X about a recent paper shared by Yusuf Ilhan et al. published in Taylor and Francis:
“Omitting bolus 5-FU in GI cancer chemotherapy: a meta-analysis
In 12,698 patients, skipping bolus 5-FU decreased grade 3-4 neutropenia (OR 0.46) and thrombocytopenia (OR 0.53) without compromising PFS or OS.
Safer option, same efficacy.”
Title: Efficacy and safety of omitting 5-fluorouracil bolus in combination chemotherapy regimens for gastrointestinal cancers: a systematic review and meta-analysis
Authors: Yusuf Ilhan, Onur Yazdan Balcık, Elif Sahın, Aysegul Merc Cetınkaya, Elvina Almuradova, Murat Bardakcı, Cigdem Dınckal, Murat Karateke, Kadriye Bır Yucel, Arif Hakan Onder, Yakup Ergun.
More posts featuring Nieves Martinez Lago.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023